Heterozygous mutations in the X-linked MECP2 gene cause the neurological disorder Rett syndrome 1 . The methyl-CpGbinding protein 2 (MeCP2) protein is an epigenetic reader whose binding to chromatin primarily depends on 5-methylcytosine 2,3 . Functionally, MeCP2 has been implicated in several cellular processes on the basis of its reported interaction with more than 40 binding partners 4 , including transcriptional co-repressors (for example, the NCoR/SMRT complex 5 ), transcriptional activators 6 , RNA 7 , chromatin remodellers 8,9 , microRNA-processing proteins 10 and splicing factors 11 . Accordingly, MeCP2 has been cast as a multi-functional hub that integrates diverse processes that are essential in mature neurons 12 . At odds with the concept of broad functionality, missense mutations that cause Rett syndrome are concentrated in two discrete clusters coinciding with interaction sites for partner macromolecules: the methyl-CpG binding domain 13 and the NCoR/SMRT interaction domain 5 . Here we test the hypothesis that the single dominant function of MeCP2 is to physically connect DNA with the NCoR/ SMRT complex, by removing almost all amino-acid sequences except the methyl-CpG binding and NCoR/SMRT interaction domains. We find that mice expressing truncated MeCP2 lacking both the N-and C-terminal regions (approximately half of the native protein) are phenotypically near-normal; and those expressing a minimal MeCP2 additionally lacking a central domain survive for over one year with only mild symptoms. This minimal protein is able to prevent or reverse neurological symptoms when introduced into MeCP2-deficient mice by genetic activation or virus-mediated delivery to the brain. Thus, despite evolutionary conservation of the entire MeCP2 protein sequence, the DNA and co-repressor binding domains alone are sufficient to avoid Rett syndrome-like defects and may therefore have therapeutic utility.
the ability to bind methylated DNA and the NCoR/SMRT complex simultaneously. We generated Δ N and Δ NC knock-in mice by replacing the endogenous Mecp2 allele in embryonic stem (ES) cells, which were used to produce germline-transmitting chimaeras (Extended Data Fig. 3 ). Truncated proteins were expressed at approximately WT levels in brain and in neurons (Extended Data Fig. 4a-d) . To assess phenotypes, knock-in mice were crossed onto a C57BL/6J background (for four generations) and cohorts underwent weekly phenotypic scoring 18, 19 or behavioural analysis. Although heterozygous female mice are the genetic model for RTT, phenotypes develop late and are mild in the case of hypomorphic Mecp2 mutations 20, 21 . Hemizygous males provide a more sensitive assay of MeCP2 function: Mecp2-null males exhibit severe phenotypes that develop shortly after weaning and median survival is nine weeks 21 . Both Δ N and Δ NC male mice were viable, fertile and showed phenotypic scores indistinguishable from WT littermates over one year ( Fig. 2a-d ). Δ N mice had normal body weight (Extended Data Fig. 4e ), whereas Δ NC mice were slightly heavier than WT littermates (Extended Data Fig. 4f ). This difference was absent in a Mecp2-null data (n = 24) 20 are shown for comparison. e-g, Behavioural analysis of separate cohorts performed at 20 weeks of age: Δ N (n = 10) and Δ NC mice (n = 10 for open field/rotarod; 11 for elevated plus maze), each compared with their WT littermates (n = 10). Graphs show individual values and medians, and statistical significance as follows: not significant (NS) P > 0.05, * P < 0.05. e, Time spent in the closed and open arms of the elevated plus maze during a 15 min trial. Genotypes were compared using Kolmogorov-Smirnov tests: Δ N closed arms, P = 0.988; and open arms, P = 0.759; Δ NC closed arms, P = 0.950; and open arms, P = 0.932. f, Time spent in the central region of the open field test was measured during a 20 min trial. Genotypes were compared using t-tests: Δ N, P = 0.822; Δ NC, * P = 0.020. g, Mean latency to fall from the accelerating rotarod in four trials was calculated for each of the 3 days of the experiment. Genotypes were compared using Kolmogorov-Smirnov tests: Δ N day 1, P = 0.759; day 2, P = 0.401; and day 3, P = 0.055; Δ NC day 1, P = 0.988; day 2, P = 0.401; and day 3, P = 0.759. Histone H3 was used as a loading control. * A non-specific band detected by the GFP antibody. For gel source data, see Supplementary Information. b, Flow cytometry analysis of protein levels in nuclei from whole brain (All) and the high-NeuN subpopulation (Neurons) in Δ NIC mice (n = 3) and WT-eGFP controls (n = 3), detected using eGFP fluorescence (AU, arbitrary units). Graph shows mean ± s.e.m. and genotypes were compared by t-test: All, * * * P = 0.0002; and Neurons, * * * P = 0.0001. c, Quantitative PCR analysis of mRNA prepared from whole brain of Δ NIC mice (n = 3) and WT-eGFP controls (n = 3). Mecp2 transcript levels were normalized to cyclophilin A mRNA. Graph shows mean ± s.e.m. Letter reSeArCH more outbred cohort (Extended Data Fig. 4g ), consistent with previous observations that body weight of Mecp2 mutants is affected by genetic background 21 .
At 20 weeks of age, cohorts were tested for RTT-like behaviours: hypoactivity, decreased anxiety and reduced motor abilities. Neither activity (distance travelled in an open field; Extended Data Fig. 4h ) nor anxiety (time spent in the open arms of the elevated plus maze; Fig. 2e ) was abnormal in Δ N and Δ NC mice, although the latter did spend longer in the centre of the open field ( Fig. 2f ), indicative of mildly decreased anxiety. Motor coordination was assessed using the accelerating rotarod test over 3 days. Whereas mouse models of RTT show impaired performance that was most striking on the third day 20, 22 , Δ N and Δ NC mice were comparable to WT littermates throughout this test ( Fig. 2g ). Overall, the results suggest that contributions of the N-and C-terminal regions to MeCP2 function are at best subtle. The result is remarkable given the presence of a neurological phenotype in male mice expressing a slightly more severe C-terminal truncation, which lacks residues beyond T308 (ref. 23) . The difference may be explained by retention of full NID function in Δ NC mice, as loss of the extra four C-terminal amino acids (309-312) markedly reduces the affinity of truncated MeCP2 for the NCoR/SMRT co-repressor complex 5 .
We next replaced the endogenous Mecp2 gene with Δ NIC, a minimal allele comprising only the MBD and NID domains and retaining 32% of the full-length protein sequence ( Fig. 1b and Extended Data Fig. 5 ). Δ NIC protein levels were reduced in whole brain (~ 50% of WT-eGFP controls; Fig. 3a , b) and in neurons (~ 40% of WT-eGFP controls; Fig. 3b ). The presence of normal levels of mRNA in Δ NIC mice ( Fig. 3c ) suggested that deletion of the intervening region compromises protein stability. Despite low protein levels, male Δ NIC mice had a normal lifespan ( Fig. 3e and Extended Data Fig. 6a ). However, phenotypic scoring over one year detected mild neurological phenotypes ( Fig. 3d ), predominantly gait abnormalities and partial hindlimb clasping. These symptoms were relatively stable throughout the scoring period. Δ NIC mice also weighed ~ 40% less than their WT littermates (Extended Data Fig. 6b ).
Behavioural analysis of a separate cohort at 20 weeks showed decreased anxiety in male Δ NIC mice, signified by reduced time spent in the closed arms of an elevated plus maze ( Fig. 3f ), although this phenotype was not detected by the open field test ( Fig. 3g ). No activity phenotype was detected in the open field (Extended Data Fig. 6c ), but, consistent with the gait defects detected by weekly scoring, Δ NIC mice displayed declining motor coordination on the accelerating rotarod over 3 days, culminating in a significantly impaired performance on the third day ( Fig. 3h ). It is noteworthy that Δ NIC animals are much less severely affected than male mice with the mildest common mutation found in RTT patients, R133C, which had a median lifespan of 42 weeks, higher phenotypic scores and a more pronounced reduction in body weight 20 (Extended Data Fig. 7 ). Reduced protein levels may contribute to the relatively mild phenotype, as mice with ~ 50% levels of full-length MeCP2 have neurological defects 24 .
To further test ∆ NIC functionality, we asked whether late genetic activation could reverse phenotypic defects in symptomatic MeCP2-deficient mice, as has previously been shown with the full-length protein 18 . Mice that were MeCP2-deficient through insertion of a floxed transcriptional STOP cassette in intron 2 of the Δ NIC gene (Extended Data Figs 5 and 8a, b) resembled Mecp2-nulls (Extended Data Fig. 8c, d ). This line was crossed with mice carrying a creER T transgene (Cre recombinase fused to a modified oestrogen receptor) to enable removal of the STOP cassette upon tamoxifen treatment. Induced expression of ∆ NIC after the onset of symptoms in STOP creER T mice ( Fig. 4a ) resulted in high levels of Cre-mediated recombination (Extended Data Fig. 9a ) and protein levels similar to those of Δ NIC mice (Extended Data Fig. 9b ). Δ NIC activation had a pronounced effect on phenotypic progression, relieving neurological symptoms and restoring normal survival (Fig. 4b, c ). Separation of the phenotypic scores into the six tested components showed clear reversal of tremor, hypoactivity and gait abnormalities (Extended Data Fig. 9c ). In contrast, control STOP mice lacking the creER T transgene developed severe symptoms and failed to survive beyond 26 weeks. Thus, despite its radically reduced length and relatively low abundance, Δ NIC was able to effectively rescue MeCP2deficient mice from RTT-like phenotypes. This finding prompted us to explore whether ∆ NIC could be used for gene therapy in Mecp2-null mice. A human version of the Δ NIC gene (hΔNIC) ( Fig. 4d ), driven by a minimal Mecp2 promoter 25 , was tagged with a short Myc epitope (in place of eGFP) and packaged into a self-complementary adeno-associated viral vector (scAAV). Neonatal mice (postnatal day 1-2) injected intra-cranially with this virus (Fig. 4d ) expressed h∆ NIC protein (Extended Data Fig. 10a ). Treated Mecp2-null mice showed reduced symptom severity and greatly extended survival compared with controls receiving vehicle alone ( Fig. 4e-g ). Despite the lack of fine control over infection rate, we did not observe deleterious effects due to overexpression, even in WT animals (Extended Data Fig. 10b-d ). It is possible that the moderate instability of h∆ NIC protein mitigates toxic effects associated with overexpression, widening the dosage window. The results also demonstrate that h∆ NIC protein is functional without the large eGFP tag. Minimal MeCP2 may therefore be therapeutically advantageous, as shortening the coding sequence creates room for additional regulatory sequences within the limited capacity of scAAV vectors, which may enable more precise control of expression.
Our findings support a simple model whereby the predominant function of MeCP2 is to recruit the NCoR/SMRT co-repressor complex to methylated sites on chromatin. This scenario agrees with recent evidence that inhibition of gene transcription is proportional to MeCP2 occupancy within gene bodies 26, 27 . Notably, minimal MeCP2 protein (∆ NIC) is missing all or part of several domains that have been highlighted as potentially important, including the AT-hooks 28 , several activity-dependent phosphorylation sites 29, 30 , an RNA binding motif 7 and interaction sites for proteins implicated in microRNA processing 10 , splicing 11 and chromatin remodelling 9 . While these parts of the protein may have biological relevance, their presence is evidently not required for prevention of the RTT-like phenotype. Importantly, the discovery that the MBD and NID are sufficient to partly restore neuronal function to MeCP2-deficient mice allowed us to explore the therapeutic potential of the minimal protein, with encouraging results. These results potentially set a precedent for reducing the length of other gene therapy constructs by identifying dispensable regions that cannot be predicted by evolutionary conservation.
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Nomenclature. According to convention, all amino-acid numbers given refer to the e2 isoform. Numbers refer to homologous amino acids in human (NCBI accession P51608) and mouse (NCBI accession Q9Z2D6) protein, until residue 385 where there is a two-amino-acid insertion in the human protein. Mutation analysis. Mutational data were collected as described previously 5 : RTT-causing missense mutations were extracted from the RettBASE data set (http://mecp2.chw.edu.au/); and polymorphisms identified in males in the general population were extracted from the Exome Aggregation Consortium database (http://exac.broadinstitute.org). Design of the truncated MeCP2 proteins. The MBD and NID were defined as residues 72-173 and 272-312, respectively. All three constructs retained the extreme N-terminal sequences encoded by exons 1 and 2, present in isoforms e1 and e2, respectively. They also include the first three amino acids of exons 3 (EEK) to preserve the splice acceptor site. The intervening region (I) was replaced in ∆ NIC by the NLS of SV40 preceded by a flexible linker. The sequence of the NLS was PKKKRKV (DNA sequence: CCCAAGAAAAAGCGGAAGGTG) and of the linker was GSSGSSG (DNA sequence: GGATCCAGTGGCAGCTCTGGG). All three proteins were C-terminally tagged with eGFP connected by a linker. To be consistent with a previous study tagging full-length MeCP2 (ref. 20) , the linker sequence CKDPPVAT (DNA sequence: TGTAAGGATCCACCGGTCGCCACC) was used to connect the C terminus of ∆ N to eGFP. To connect the NID to the eGFP tag in ∆ NC and ∆ NIC, the flexible GSSGSSG linker was used instead (DNA sequence: GGGAGCTCCGGCAGTTCTGGA). For expression in cultured cells, cDNA sequences encoding e2 isoforms of the MeCP2 deletion series were synthesized (GeneArt, Thermo Fisher Scientific) and cloned into the pEGFP-N1 vector (Clontech) using XhoI and NotI restriction sites (NEB). Point mutations (R111G and R306C) were inserted into the WT-eGFP plasmid using a QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies). Primer sequences for R111G were as follows: forward TGGACACGAAAGCTTAAACAAGGGAAGTCTGGCC and reverse GGCCAGACTTCCCTTGTTTAAGCTTTCGTGTCCA; and for R306C: forward CTCCCGGGTCTTGCACTTCTTGATGGGGA and reverse TCCCCATCAAGAAGTGCAAGACCCGGGAG. For ES cell targeting, genomic sequences encoding exons 3 and 4 of the eGFP-tagged truncated proteins were synthesized (GeneArt, Thermo Fisher Scientific) and cloned into a previously used 18 targeting vector using MfeI restriction sites (NEB). This vector contained a neomycin resistance gene followed by a transcriptional STOP cassette flanked by loxP sites ('floxed') in intron 2. Cell culture. HeLa and NIH-3T3 cells were originally from a standard repository (such as American Type Culture Collection, ATCC) and maintained in the Bird laboratory for many years. HeLa and NIH-3T3 cells were grown in DMEM (Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco) and 1% penicillin-streptomycin (Gibco). ES cells were grown in Glasgow MEM (Gibco) supplemented with 10% FBS (Gibco, batch tested), 1% non-essential amino acids (Gibco), 1% sodium pyruvate (Gibco), 0.1% β -mercaptoethanol (Gibco) and 1,000 units ml −1 LIF (ESGRO). Low-passage ES cells were a gift from A. Smith, Institute for Stem Cell Research, University of Edinburgh. They were received at passage 12 and frozen in aliquots (mycoplasma-free). Laboratory stocks of HeLa and NIH-3T3 cells were periodically tested for mycoplasma. Immunoprecipitation. HeLa cells were transfected with pEGFP-N1-MeCP2 plasmids using JetPEI (PolyPlus Transfection) and harvested after 24-48 h. Nuclear extracts were prepared using Benzonase (Sigma) and 150 mM NaCl, and MeCP2-eGFP complexes were captured using GFP-Trap_A beads (Chromotek) as described previously 5 . Proteins were analysed by western blotting using antibodies against GFP (NEB 2956), NCoR (Bethyl A301-146A), HDAC3 (Sigma 3E11) and TBL1XR1 (Bethyl A300-408A), all at a dilution of 1:1,000; followed by LI-COR secondary antibodies: IRDye 800CW Donkey anti-Mouse (926-32212) and IRDye 800CW Donkey anti-Rabbit (926-32213) or IRDye 680LT Donkey anti-Rabbit (926-68023) at a dilution of 1:10,000. MeCP2 localization and TBL1X-mCherry recruitment assay. NIH-3T3 cells were seeded on coverslips in six-well plates (25,000 cells per well) and transfected with 2 μ g plasmid DNA (pEGFP-N1-MeCP2 alone or pEGFP-N1-MeCP2 and pmCherry-N1-TBL1X 5 ) using JetPEI (PolyPlus Transfection). After 48 h, cells were fixed with 4% (w/v) paraformaldehyde (Sigma), stained with 4′ ,6-diamidino-2-phenylindole (DAPI; Sigma) and then mounted using ProLong Diamond (Life Technologies). Fixed cells were photographed on a confocal microscope (Leica SP5; 63× objective) using LAS AF software (Leica). The number of co-transfected cells with TBL1X-mCherry recruitment to heterochromatic foci was determined for each MeCP2 construct. In total, 113-125 cells per construct were counted (from three independent transfection experiments). This analysis was performed blind. The total proportion of cells with TBL1X-mCherry recruitment by each mutant MeCP2 protein was compared with WT using Fisher's exact tests.
Generation of knock-in mice. Targeting vectors were introduced into 129/Ola E14 TG2a ES cells by electroporation, and G418-resistant clones with correct targeting at the Mecp2 locus were identified by PCR and Southern blot screening. CRISPR-Cas9 technology was used to increase the targeting efficiency of Δ N and Δ NIC lines: the guide RNA sequence (GGTTGTGACCCGCCATGGAT) was cloned into pX330-U6-Chimeric_BB-CBh-hSpCas9 (a gift from F. Zhang; Addgene plasmid 42230 (ref. 31)), which was introduced into the ES cells with the targeting vectors. This introduced a double-strand cut in intron 2 of the wild-type gene (at the site of the NeoSTOP cassette in the targeting vector). Mice were generated from ES cells as previously described 21 . The 'floxed' NeoSTOP cassette was removed in vivo by crossing chimaeras with homozygous females from the transgenic CMV-cre deleter strain (JAX stock 006054) on a C57BL/6J background. The CMV-cre transgene was subsequently bred out. All mice used in this study were bred and maintained at the Universities of Edinburgh or Glasgow animal facilities under standard conditions, and procedures were carried out by staff licensed by the UK Home Office and in accordance with the Animal and Scientific Procedures Act 1986. Knock-in mice were caged with their WT littermates. Biochemical characterization of knock-in mice. For biochemical analysis, brains were harvested by snap-freezing in liquid nitrogen at 6-13 weeks of age, unless otherwise stated. Brains of hemizygous male mice were used for all analysis, unless otherwise stated. For Southern blot analysis, half brains were homogenized in 50 mM Tris HCl pH 7.5, 100 mM NaCl, 5 mM EDTA and treated with 0.4 mg ml −1 proteinase K in 1% SDS at 55 °C overnight. Samples were treated with 0.1 mg ml −1 RNaseA for 1-2 h at 37 °C, before phenol:chloroform extraction of genomic DNA. Genomic DNA was purified from ES cells using Puregene Core Kit A (Qiagen) according to the manufacturer's instructions for cultured cells. Genomic DNA was digested with restriction enzymes (NEB), separated by agarose gel electrophoresis and transferred onto ZetaProbe membranes (BioRad). DNA probes homologous to either exon 4 or the end of the 3′ homology arm were radioactively labelled with [α 32]dCTP (Perkin Elmer) using the Prime-a-Gene Labelling System (Promega). Blots were probed overnight, washed and exposed in Phosphorimager cassettes (GE Healthcare) before scanning on a Typhoon FLA 7000. Bands were quantified using ImageQuant software.
Protein levels in whole-brain crude extracts were quantified using western blotting. Extracts were prepared as described previously 20 , and blots were probed with antibodies against GFP (NEB 2956) at a dilution of 1:1,000, followed by LI-COR secondary antibodies (listed above). Histone H3 (Abcam ab1791) was used as a loading control (dilution 1:10,000). Levels were quantified using Image Studio Lite version 4.0 software and compared using t-tests. WT-eGFP mice 20 were used as controls. Three biological replicates of each genotype were analysed, except for the reversal experiment where five STOP creER T + Tmx animals and one STOP + Tmx animal were analysed.
For flow cytometry analysis, fresh brains were harvested from 12-week-old animals and Dounce-homogenized in 5 ml homogenization buffer (320 mM sucrose, 5 mM CaCl 2 , 3 mM Mg(Ac) 2 , 10 mM Tris HCl pH 7.8, 0.1 mM EDTA, 0.1% NP40, 0.1 mM PMSF, 14.3 mM β -mercaptoethanol, protease inhibitors (Roche)), and 5 ml of 50% OptiPrep gradient centrifugation medium (50% Optiprep (Sigma D1556-250ML), 5 mM CaCl 2 , 3 mM Mg(Ac) 2 , 10 mM Tris HCl pH 7.8, 0.1 M PMSF, 14.3 mM β -mercaptoethanol) was added. This was layered on top of 10 ml of 29% OptiPrep solution (v/v in H 2 O, diluted from 60% stock) in Ultra-Clear Beckman Coulter centrifuge tubes, and samples were centrifuged at 10,100g for 30 min, 4 °C. Pelleted nuclei were resuspended in resuspension buffer (20% glycerol in DPBS (Gibco) with protease inhibitors (Roche)). For flow cytometry analysis, nuclei were pelleted at 600g (5 min, 4 °C), washed in 1 ml PBTB (5% (w/v) BSA, 0.1% Triton X-100 in DPBS with protease inhibitors (Roche)) and then resuspended in 250 μ l PBTB. To stain for NeuN, NeuN antibody (Millipore MAB377) was conjugated to Alexa Fluor 647 (APEX Antibody Labelling Kit, Invitrogen A10475), added at a dilution of 1:125 and incubated under rotation for 45 min at 4 °C. Flow cytometry (BD LSRFortessa SORP using FACSDIVA version 8.0.1 software) was used to obtain the mean eGFP fluorescence for the total nuclei (n = 50,000 per sample) and the high-NeuN (neuronal) subpopulation (n > 8,000 per sample). Three biological replicates of each genotype were analysed. The protein levels of the novel mouse lines were compared with WT-eGFP controls using t-tests. To compare protein levels in WT-eGFP mice with WT littermates, nuclei were also stained with an MeCP2 antibody (Sigma M7443) conjugated to Alexa Fluor 568 (APEX Antibody Labelling Kit, Invitrogen A10494) at a dilution of 1:125.
To determine mRNA levels, RNA was purified and reverse transcribed from half brains (harvested at 11 weeks of age); and Mecp2 and cyclophilin A transcripts were analysed by qPCR using LightCycler 480 SW 1.5 software as previously described 20 . Three biological replicates of each genotype were analysed, each pipetted in triplicate. mRNA levels in Δ NIC mice were compared with WT-eGFP controls using a t-test.
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Phenotypic characterization of knock-in mice. Consistent with a previous study 20 , mice were backcrossed for four generations to reach ~ 94% C57BL/6J before undergoing phenotypic characterization. Two separate cohorts, each consisting of 10 mutant animals (11 for Δ NC elevated plus maze) and 10 WT littermates, were produced for each novel knock-in line. One cohort was scored and weighed regularly from 4 to 52 weeks of age as previously described 18, 19 . Survival was graphed using Kaplan-Meier plots. Preliminary outbred (75% C57BL/6J) cohorts of ΔNC and ΔNIC strains were also analysed: ΔNC cohort, ΔNC n = 7 and WT littermates, n = 9; ΔNIC cohort, ΔNIC n = 10 and WT littermate, n = 1. Previously published 20 data for Mecp2-null and R133C-eGFP (both backcrossed onto C57BL/6J) were included for comparison. The second backcrossed cohorts underwent behavioural analysis at 20 weeks of age (see refs 19, 20 for detailed protocols). Tests were performed over a 2 week period: elevated plus maze on day 1, open field test on day 2, and accelerating rotarod test on days 6-9 (1 day of training followed by 3 days of trials). All analysis was performed blind to genotype. Animals were randomly assigned to the two backcrossed cohorts and the order in which they were analysed was randomized. In a previous study, cohorts of this size were sufficient to show statistically significant differences between mice expressing patient mutations and their WT littermates in the same behavioural tests 20 . This cohort size was therefore considered sufficient to be confident of an absence of the same phenotypes in the asymptomatic novel lines. Statistical analysis. Growth curves were compared using repeated measures ANOVA (the animals that died within the experimental period-one WT in each ∆ NC cohort and one ∆ NIC in their cohort-were excluded from this analysis to enable a balanced design). Survival curves were compared using a Mantel-Cox test. For behavioural analysis, when all data fitted a normal distribution (open field centre time and distance travelled), genotypes were compared using t-tests (unpaired, two-tailed). For non-parametric datasets (elevated plus maze time in arms/centre and accelerating rotarod latency to fall), genotypes were compared using Kolmogorov-Smirnov tests. Change in performance over time in the accelera ting rotarod test was determined using Friedman tests. All analysis was performed using GraphPad Prism 7 software. Genetic activation of minimal MeCP2 (ΔNIC). Transcriptionally silent minimal Mecp2 (Δ NIC) was activated in symptomatic null-like STOP mice following the procedure used in ref. 18 . In short, the Δ NIC Mecp2 allele was inactivated by the retention of the NeoSTOP cassette in intron 2 by mating chimaeras with WT females instead of CMV-cre deleter mice. Resulting STOP/+ females were crossed with heterozygous creER T transgenic males (JAX stock 004682) to produce males of four genotypes (87.5% C57BL/6J). A cohort consisting of all four genotypes WT (n = 4), WT creER T (n = 4), STOP (n = 9) and STOP creER T (n = 9), was scored and weighed weekly from 4 weeks of age. When STOP and STOP creER T mice displayed RTT-like symptoms, all individuals were given a series of tamoxifen injections: one at 6 weeks of age, one at 7 weeks of age, and five daily injections at 8 weeks of age, each at a dose of 100 μ g/g (body weight). Brain tissue from tamoxifen-treated STOP creER T (n = 8), WT (n = 1) and WT creER T (n = 1) animals was harvested at 28 weeks of age (after successful symptom reversal in STOP creER T mice) for biochemical analysis. Brain tissue from one tamoxifen-treated STOP mouse (harvested at its humane end-point) was also included in the biochemical analysis (methods described above). Vector delivery of minimal MeCP2 (ΔNIC). The AAV vector expressing minimal MeCP2 (∆ NIC) was tested in Mecp2-null and WT mice maintained on a C57BL/6J background. Self-complementary AAV (scAAV) particles, comprising AAV2 ITRflanked genomes packaged into AAV9 capsids, were generated at the University of North Carolina Vector Core. Particles were produced as previously described 32 by transfection of HEK293 cells with helper plasmids (pXX6-80, pGSK2/9) and a plasmid containing the ITR-flanked construct in the presence of polyethyleneimine (Polysciences). For translational relevance, the ∆ NIC-expressing construct used the equivalent human MECP2_e1 coding sequence tagged with a small C-terminal Myc epitope to replace the eGFP tag used in knock-in experiments. The transgene was under the control of an endogenous Mecp2 promoter fragment as previously described 25 . Vector was formulated in high-salt PBS (containing 350 mM total NaCl) supplemented with 5% sorbitol. Virus (3 μ l per site; dose = 1 × 10 11 viral genomes per mouse) was injected bilaterally into the neuropil of unanaesthetized postnatal day (P)1/2 males, as described previously 33 . Control injections used the same diluent without vector (vehicle control). Animals were selected at random for injection with the vector or vehicle control. The injected pups were returned to the home cage and assessed weekly from 5 weeks of age, as described above (performed blind to genotype). Cohorts were as follows: WT + vehicle (n = 15); Mecp2-null + vehicle (n = 20; 19 of which were scored as one reached its humane end-point early); WT + hΔ NIC (n = 14); and Mecp2-null + hΔ NIC (n = 17).
To validate the expression of virally delivered hΔ NIC, mice were deeply anaesthetized with pentobarbitone (50 mg, intraperitoneally) and transcardially perfused with 4% (w/v) paraformaldehyde (in 0.1 M PBS). A vibrating microtome (Leica VT1200) was used to obtain 70 μ m sections of the brain. Sections were washed three times in 0.3 M PBS followed by blocking using 5% (w/v) normal goat serum with 0.3% (v/v) Triton X-100 in 0.3 M PBS (PBST) for 1 h at room temperature. Samples were then incubated for 48 h on a shaker at 4 °C with primary antibodies against Myc (Abcam ab9106; 1:500 dilution) and NeuN (Abcam 104224; 1:500 dilution). Samples were washed three times with 0.3 M PBST and incubated with secondary antibodies (Alexa Fluor 594 goat anti-rabbit (Abcam 150080; 1:500 dilution) and Alexa Fluor 647 goat anti-mouse (Stratech scientific LTD, 115-605-003JIR; 1:500 dilution)) at 4 °C overnight. Finally, sections were incubated with DAPI (Sigma; 1:1,000) for 30 min at room temperature before mounting with Fluoroshield with DAPI (Sigma, F6057). Z-series at 0.6-1.3 μ m intervals were captured using a Zeiss LSM710 or Zeiss Axiovert LSM510 laser confocal microscope (40× objective). To estimate transduction efficiency, the ratio of Mycpositive nuclei to DAPI-stained nuclei was calculated from random sections of hippocampus (CA1), layer 5 of primary motor cortex, thalamus, hypothalamus and brainstem (n = 3 mice per genotype, 27 fields from each brain region). Mecp2null + hΔ NIC mice were analysed after reaching their humane endpoints (aged 33, 35 and 36 weeks). WT + hΔ NIC mice were harvested for analysis at 4 weeks of age. Data availability. All data are available from the corresponding author upon reasonable request. Source Data underlying all graphs and full scans of all western and Southern blots are included in the online version of the paper. 
Extended Data Figure 4 | ΔN and ΔNC knock-in mice express truncated proteins at approximately WT levels and display minimal phenotypes. a, Western blot analysis of whole-brain extract showing protein sizes and abundance of MeCP2 in Δ N and Δ NC mice and WT-eGFP controls, detected using a GFP antibody. Histone H3 was used as a loading control. * A non-specific band detected by the GFP antibody. For gel source data, see Supplementary Information. b, Flow cytometry analysis of protein levels in nuclei from whole brain (All) and the high-NeuN subpopulations (Neurons) in WT-eGFP (n = 3), Δ N (n = 3) and Δ NC (n = 3) mice, detected using eGFP fluorescence. Graph shows mean ± s.e.m. and genotypes were compared with WT-eGFP controls by t-test: All ∆ N, P = 0.338; ∆ NC, * * P = 0.003; and Neurons ∆ N, P = 0.672; ∆ NC, * P = 0.014. au, arbitrary units. c, Flow cytometry analysis of protein levels in WT (n = 3) and WT-eGFP (n = 3) mice, detected using an MeCP2 antibody. Graph shows mean ± s.e.m. and genotypes were compared by t-test: All, P = 0.214; and Neurons, P = 0.085. d, Example histogram (of one WT-eGFP sample) showing how the Neuronal subpopulation was defined according to NeuN-AF647 staining. e-g, Growth curves of the backcrossed scoring cohorts (e, f; see Fig. 2a-d) and an outbred (g; 75% C57BL/6J) cohort of Δ NC mice (n = 7) and WT littermates (n = 9). Graphs show mean values ± s.e.m. Genotypes were compared using repeated measures ANOVA: ΔN , P = 0.362; Δ NC, * * * * P < 0.0001; Δ NC (outbred), P = 0.739. Mecp2-null data (n = 20) 20 are shown for comparison to the backcrossed cohorts. h, Behavioural analysis of Δ N (n = 10) and Δ NC mice (n = 10) each compared with their WT littermates (n = 10) at 20 weeks of age (see Fig. 2e-g) . Total distance travelled in the open field test was measured during a 20 min trial. Graphs show individual values and medians. Genotypes were compared using t-tests: Δ N, P = 0.691; Δ NC, P = 0.791. NS, not significant.
